Logo image of ZJYL

JIN MEDICAL INTERNATIONAL LT (ZJYL) Stock Fundamental Analysis

NASDAQ:ZJYL - KYG5140V1124 - Common Stock

0.66 USD
+0 (+0.7%)
Last: 9/3/2025, 8:00:02 PM
Fundamental Rating

4

Overall ZJYL gets a fundamental rating of 4 out of 10. We evaluated ZJYL against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of ZJYL get a neutral evaluation. Nothing too spectacular is happening here. ZJYL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ZJYL had positive earnings in the past year.
ZJYL had a negative operating cash flow in the past year.
ZJYL had positive earnings in each of the past 5 years.
ZJYL had a positive operating cash flow in 4 of the past 5 years.
ZJYL Yearly Net Income VS EBIT VS OCF VS FCFZJYL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

1.2 Ratios

With an excellent Return On Assets value of 8.03%, ZJYL belongs to the best of the industry, outperforming 90.53% of the companies in the same industry.
The Return On Equity of ZJYL (12.76%) is better than 88.95% of its industry peers.
ZJYL's Return On Invested Capital of 7.79% is amongst the best of the industry. ZJYL outperforms 85.26% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ZJYL is in line with the industry average of 8.46%.
Industry RankSector Rank
ROA 8.03%
ROE 12.76%
ROIC 7.79%
ROA(3y)9.9%
ROA(5y)10.46%
ROE(3y)14.18%
ROE(5y)16.34%
ROIC(3y)9.49%
ROIC(5y)11.9%
ZJYL Yearly ROA, ROE, ROICZJYL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

ZJYL has a better Profit Margin (15.64%) than 92.63% of its industry peers.
In the last couple of years the Profit Margin of ZJYL has declined.
ZJYL has a better Operating Margin (15.48%) than 85.79% of its industry peers.
In the last couple of years the Operating Margin of ZJYL has declined.
Looking at the Gross Margin, with a value of 40.43%, ZJYL is doing worse than 67.89% of the companies in the same industry.
ZJYL's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 15.48%
PM (TTM) 15.64%
GM 40.43%
OM growth 3Y6.9%
OM growth 5Y-6.46%
PM growth 3Y7.26%
PM growth 5Y-2.67%
GM growth 3Y9.69%
GM growth 5Y1.86%
ZJYL Yearly Profit, Operating, Gross MarginsZJYL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

ZJYL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, ZJYL has more shares outstanding
The number of shares outstanding for ZJYL has been reduced compared to 5 years ago.
The debt/assets ratio for ZJYL is higher compared to a year ago.
ZJYL Yearly Shares OutstandingZJYL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ZJYL Yearly Total Debt VS Total AssetsZJYL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 5.79 indicates that ZJYL is not in any danger for bankruptcy at the moment.
ZJYL's Altman-Z score of 5.79 is amongst the best of the industry. ZJYL outperforms 83.68% of its industry peers.
A Debt/Equity ratio of 0.39 indicates that ZJYL is not too dependend on debt financing.
ZJYL's Debt to Equity ratio of 0.39 is in line compared to the rest of the industry. ZJYL outperforms 45.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z 5.79
ROIC/WACC1.08
WACC7.2%
ZJYL Yearly LT Debt VS Equity VS FCFZJYL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 2.50 indicates that ZJYL has no problem at all paying its short term obligations.
With a Current ratio value of 2.50, ZJYL perfoms like the industry average, outperforming 51.58% of the companies in the same industry.
ZJYL has a Quick Ratio of 2.19. This indicates that ZJYL is financially healthy and has no problem in meeting its short term obligations.
ZJYL has a Quick ratio (2.19) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 2.19
ZJYL Yearly Current Assets VS Current LiabilitesZJYL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.76% over the past year.
ZJYL shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
Looking at the last year, ZJYL shows a quite strong growth in Revenue. The Revenue has grown by 18.57% in the last year.
ZJYL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.90% yearly.
EPS 1Y (TTM)15.76%
EPS 3Y5.52%
EPS 5Y3.28%
EPS Q2Q%66.67%
Revenue 1Y (TTM)18.57%
Revenue growth 3Y4.22%
Revenue growth 5Y2.9%
Sales Q2Q%35.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZJYL Yearly Revenue VS EstimatesZJYL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 33.00, ZJYL can be considered very expensive at the moment.
73.16% of the companies in the same industry are more expensive than ZJYL, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.84. ZJYL is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 33
Fwd PE N/A
ZJYL Price Earnings VS Forward Price EarningsZJYL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ZJYL is valued cheaply inside the industry as 80.53% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.54
ZJYL Per share dataZJYL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

The decent profitability rating of ZJYL may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)10.07
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ZJYL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JIN MEDICAL INTERNATIONAL LT

NASDAQ:ZJYL (9/3/2025, 8:00:02 PM)

0.66

+0 (+0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.64%
Inst Owner Change-32.36%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap103.32M
AnalystsN/A
Price TargetN/A
Short Float %0.3%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 33
Fwd PE N/A
P/S 4.4
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB 3.73
EV/EBITDA 14.54
EPS(TTM)0.02
EY3.03%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.15
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)10.07
Profitability
Industry RankSector Rank
ROA 8.03%
ROE 12.76%
ROCE 12.7%
ROIC 7.79%
ROICexc 23.55%
ROICexgc 25.79%
OM 15.48%
PM (TTM) 15.64%
GM 40.43%
FCFM N/A
ROA(3y)9.9%
ROA(5y)10.46%
ROE(3y)14.18%
ROE(5y)16.34%
ROIC(3y)9.49%
ROIC(5y)11.9%
ROICexc(3y)22.47%
ROICexc(5y)22.7%
ROICexgc(3y)23.46%
ROICexgc(5y)23.49%
ROCE(3y)12.88%
ROCE(5y)15.84%
ROICexcg growth 3Y-2.39%
ROICexcg growth 5Y-7.19%
ROICexc growth 3Y-4.58%
ROICexc growth 5Y-8.54%
OM growth 3Y6.9%
OM growth 5Y-6.46%
PM growth 3Y7.26%
PM growth 5Y-2.67%
GM growth 3Y9.69%
GM growth 5Y1.86%
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA 2.84
Cap/Depr 324.82%
Cap/Sales 4.78%
Interest Coverage 15.2
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 2.19
Altman-Z 5.79
F-Score3
WACC7.2%
ROIC/WACC1.08
Cap/Depr(3y)128.78%
Cap/Depr(5y)88.37%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.76%
EPS 3Y5.52%
EPS 5Y3.28%
EPS Q2Q%66.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)18.57%
Revenue growth 3Y4.22%
Revenue growth 5Y2.9%
Sales Q2Q%35.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.9%
EBIT growth 3Y11.4%
EBIT growth 5Y-3.75%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-177.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.86%
OCF growth 3YN/A
OCF growth 5YN/A